How Advocates Are Advancing a Treatment for an Ultra-Rare Disease

Dan Williams, co-founder and CEO of SynaptixBio, discusses the ultra-rare and deadly leukodystrophy H-ABC, how the company’s experimental therapy works, and the role patient advocates have played in the company’s efforts to advance its experimental therapy.